+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Polycystic Kidney Disease (PKD) - Epidemiology Forecast to 2028

  • ID: 4845142
  • Report
  • September 2019
  • Region: Global
  • 70 pages
  • DelveInsight
1 of 2
‘Polycystic Kidney Disease (PKD)- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Polycystic Kidney Disease in the 10 Emerging Markets (EM) ,i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

Geography Covered
  • Asia (China and Taiwan)
  • Middle East (Turkey, Saudi Arabia, UAE)
  • Eastern Europe (Russia)
  • LATAM (Brazil, Mexico, Colombia and Argentina)
Study Period:2017-2028

Polycystic Kidney Disease Disease Understanding

Polycystic kidney disease (PKD) is part of a heterogeneous group of disorders characterized by renal cysts and numerous systemic and extrarenal manifestations. In patients with PKD, the kidneys contain multiple fluid-filled cysts. People with PKD can also have cysts in the liver (mainly) and problems in other organs, such as the heart and blood vessels in the brain. Although PKD is inherited monogenically, it is phenotypically, genetically, and allelically heterogeneous.

Polycystic Kidney Disease Epidemiology

The Polycystic Kidney Disease (PKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. The epidemiology data for Polycystic Kidney Disease are studied through all possible division to give a better understanding about the Disease scenario in 10EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Polycystic Kidney Disease Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Polycystic Kidney Disease, gender-specific cases of PKD, clinical manifestations in Patients of ADPKD and transplant eligible PKD Patients) scenario of Polycystic Kidney Disease (PKD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.

The Report also provides the epidemiology trends observed in the 10EM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this report, the total number of prevalent cases of Polycystic Kidney Disease (PKD) in 10EM was found to be 1,912,820, in the year 2017.

Report Scope
  • The report covers detailed overview of Polycystic Kidney Disease explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Polycystic Kidney Disease in 10 emerging markets covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.
The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 10EM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by total prevalent population, total diagnosed cases of Polycystic Kidney Disease, gender-specific cases of PKD, clinical manifestations in Patients of ADPKD and transplant eligible PKD Patients in 10EM
Key Strengths
  • 10 Year Forecast of Polycystic Kidney Disease epidemiology
  • 10EM Coverage
  • Total Prevalent Cases of PKDs
  • Prevalent Cases according to segmentation: total prevalent population, total diagnosed cases of Polycystic Kidney Disease, gender-specific cases of PKD, clinical manifestations in Patients of ADPKD and transplant eligible PKD Patients
Key Assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. PKD Market Overview at a Glance
2.1. Market Share (%) Distribution of PKD in 2017
2.2. Market Share (%) Distribution of PKD in 2028

3. Disease Background and Overview
3.1. Introduction
3.2. Types
3.3. Causes
3.4. Risk Factors
3.5. Signs and symptoms
3.6. Pathophysiology
3.7. Diagnosis
3.8. Biomarkers
3.9. Other Complications associated with PKD

4. Epidemiology and Patient Population - By Region
4.1. Key Findings
4.2. KOL views

5. Ten Emerging Markets (EM) Total Prevalent Population of Polycystic kidney disease (PKD)
5.1. Total Prevalence of PKD in 10 Emerging Markets
5.2. Prevalence of AD-PKD in 10 Emerging Markets

6. Region Wise-Epidemiology of Polycystic kidney disease (PKD)
6.1. Asia and East Europe (China, Taiwan, Saudi Arabia, UAE, Russia, and Turkey)
6.1.1. Assumptions and Rationale:
6.1.1.1. China
6.1.1.2. Total Prevalent Cases of PKD in China
6.1.1.2.1. Prevalence of PKD by Types in China
6.1.1.2.2. Prevalent Cases of PKD by Gender in China
6.1.1.2.3. Diagnosed Prevalence of PKD in China
6.1.1.2.4. Clinical Manifestations in Patients of ADPKD in China
6.1.1.2.5. Transplant Eligible PKD Patients in China
6.1.1.3. Taiwan
6.1.1.3.1. Total Prevalent Cases of PKD in Taiwan
6.1.1.3.2. Prevalence of PKD by Types in Taiwan
6.1.1.3.3. Prevalent Cases of PKD by Gender in Taiwan
6.1.1.3.4. Diagnosed Prevalence of PKD in Taiwan
6.1.1.3.5. Clinical Manifestations in Patients of ADPKD in Taiwan
6.1.1.3.6. Transplant Eligible PKD Patients in Taiwan
6.1.1.4. Saudi Arabia
6.1.1.4.1. Total Prevalent Cases of PKD in Saudi Arabia
6.1.1.4.2. Prevalence of PKD by Types in Saudi Arabia
6.1.1.4.3. Prevalent Cases of PKD by Gender in Saudi Arabia
6.1.1.4.4. Diagnosed Prevalence of PKD in Saudi Arabia
6.1.1.4.5. Clinical Manifestations in Patients of ADPKD in Saudi Arabia
6.1.1.4.6. Transplant Eligible PKD Patients in Saudi Arabia
6.1.1.5. UAE
6.1.1.5.1. Total Prevalent Cases of PKD in UAE
6.1.1.5.2. Prevalence of PKD by Types in UAE
6.1.1.5.3. Prevalent Cases of PKD by Gender in UAE
6.1.1.5.4. Diagnosed Prevalence of PKD in UAE
6.1.1.5.5. Clinical Manifestations in Patients of ADPKD in UAE
6.1.1.5.6. Transplant Eligible PKD Patients in UAE
6.1.1.6. Turkey
6.1.1.6.1. Total Prevalent Cases of PKD in Turkey
6.1.1.6.2. Prevalence of PKD by Types in Turkey
6.1.1.6.3. Prevalent Cases of PKD by Gender in Turkey
6.1.1.6.4. Diagnosed Prevalence of PKD in Turkey
6.1.1.6.5. Clinical Manifestations in Patients of ADPKD in Turkey
6.1.1.6.6. Transplant Eligible PKD Patients in Turkey
6.1.1.7. Russia
6.1.1.7.1. Total Prevalent Cases of PKD in Russia
6.1.1.7.2. Prevalence of PKD by Types in Russia
6.1.1.7.3. Prevalent Cases of PKD by Gender in Russia
6.1.1.7.4. Diagnosed Prevalence of PKD in Russia
6.1.1.7.5. Clinical Manifestations in Patients of ADPKD in Russia
6.1.1.7.6. Transplant Eligible PKD Patients in Russia
6.2. LATAM (Colombia, Brazil, Argentina, and Mexico)
6.2.1. Assumptions and Rationale:
6.2.1.1. Colombia
6.2.1.1.1. Total Prevalent Cases of PKD in Colombia
6.2.1.1.2. Prevalence of PKD by Types in Colombia
6.2.1.1.3. Prevalent Cases of PKD by Gender in Colombia
6.2.1.1.4. Diagnosed Prevalence of PKD in Colombia
6.2.1.1.5. Clinical Manifestations in Patients of ADPKD in Colombia
6.2.1.1.6. Transplant Eligible PKD Patients in Colombia
6.2.1.2. Brazil
6.2.1.2.1. Total Prevalent Cases of PKD in Brazil
6.2.1.2.2. Prevalence of PKD by Types in Brazil
6.2.1.2.3. Prevalent Cases of PKD by Gender in Brazil
6.2.1.2.4. Diagnosed Prevalence of PKD in Brazil
6.2.1.2.5. Clinical Manifestations in Patients of ADPKD in Brazil
6.2.1.2.6. Transplant Eligible PKD Patients in Brazil
6.2.1.3. Argentina
6.2.1.3.1. Total Prevalent Cases of PKD in Argentina
6.2.1.3.2. Prevalence of PKD by Types in Argentina
6.2.1.3.3. Prevalent Cases of PKD by Gender in Argentina
6.2.1.3.4. Diagnosed Prevalence of PKD in Argentina
6.2.1.3.5. Clinical Manifestations in Patients of ADPKD in Argentina
6.2.1.3.6. Transplant Eligible PKD Patients in Argentina
6.2.1.4. Mexico
6.2.1.4.1. Total Prevalent Cases of PKD in Mexico
6.2.1.4.2. Prevalence of PKD by Types in Mexico
6.2.1.4.3. Prevalent Cases of PKD by Gender in Mexico
6.2.1.4.4. Diagnosed Prevalence of PKD in Mexico
6.2.1.4.5. Clinical Manifestations in Patients of ADPKD in Mexico
6.2.1.4.6. Transplant Eligible PKD Patients in Mexico

7. Appendix
7.1. Report Methodology

8. Capabilities

9. Disclaimer

10. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll